Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Compass Therapeutics, reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Compass Therapeutics, announced earnings per share of $-0.12 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.10 on revenue of $0.00.
Compass Therapeutics, 's are down 28.9% and is trading at $4.19 , still down 3.46% from its 52 week high of $4.34 set on Tuesday, November 8, 2022.
Compass Therapeutics, shares lost 1.41% to trade at $4.19 in intra-day trade the report.
Compass Therapeutics, follows other major Healthcare sector earnings this month
Compass Therapeutics,'s report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar